



DEPARTMENT OF **HEALTH & HUMAN SERVICES**

Public Health Service

Food and Drug Administration
Rockville MD 20857

DEC 23 1999

0608 55 05 29 19 99

Kathleen D. Jaeger, Esq.
McKenna & Cuneo, L.L.P.
1900 K Street, N.W.
Washington, DC 20006

Re: Docket No. 99P-2146/CP1

Dear Ms. Jaeger:

I am writing to inform you that the Food and Drug **Administration (FDA)** has not resolved the issues raised in your citizen petition dated June **30, 1999**. Your **petition** requests that FDA designate Merck & Co., Inc.'s **Fosamax (alendronate sodium)** 10 milligram (mg) oral tablets **as an alternate reference listed drug to Fosamax** 40 mg oral tablets.

This interim response is provided in **accordance** with FDA regulations on citizen petitions (21 **CFR 10.30(e)(2)**). We will respond to **your** petition as soon as we have reached a decision on your request.

sincerely yours,
Janet A. Woodcock for JW

Janet Woodcock, M.D.

Director

Center for Drug Evaluation and Research

99P-2146

LET 1